Emblaveo
Payments companies reported to CMS as associated with Emblaveo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Emblaveo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Emblaveo
These are the largest totals companies reported as associated with Emblaveo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Joshua Rosenberg | Brooklyn, NY | Critical Care Medicine (Internal Medicine) | $77,080.77 |
| James Mckinnell | Torrance, CA | Infectious Disease | $48,931.22 |
| Christian Sandrock | Sacramento, CA | Internal Medicine | $42,981.56 |
| Vipul Ganatra | Phoenix, AZ | Infectious Disease | $25,232.41 |
| Martin Gnoni | Louisville, KY | Infectious Disease | $24,658.58 |
| Juan Diaz | Altamonte Springs, FL | Infectious Disease | $21,884.85 |
| Thuan Le | Murrieta, CA | Infectious Disease | $18,686.04 |
| Matthew Brown | Valdosta, GA | Infectious Disease | $18,422.03 |
| Kerry Cleveland | Memphis, TN | Infectious Disease | $14,595.29 |
| Fadi Al Akhrass | Pikeville, KY | Infectious Disease | $12,939.26 |
Prescribed Emblaveo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.